Literature DB >> 28111877

Patterns and influences in health-related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP Cohort.

Adolfo Flores1, Robert J Klaassen2, George R Buchanan1, Cindy E Neunert3.   

Abstract

BACKGROUND: Relationships between clinical/demographic factors and health-related quality of life (HRQoL) in childhood immune thrombocytopenia (ITP) remain poorly understood. Recent studies reveal conflicting information about factors that contribute to HRQoL.
METHODS: This was a prospective, single-institution, cohort study of newly diagnosed children with ITP. Serial evaluations of HRQoL were performed using the Kid's ITP Tools (KIT), scored from 0 (worst) to 100 (best), at enrollment and 1 week, 6 months, and 12 months following diagnosis. All visits included bleeding severity grading. Relationships between HRQoL and platelet count, treatment, bleeding severity, and course of disease were examined.
RESULTS: A total of 99 children with newly diagnosed ITP were evaluable for analysis. KIT scores were low at diagnosis for parents (median 26, range 15-43) and children (median 65, range 55-81) and were not influenced by age or platelet count. At diagnosis, children who received treatment had lower platelet counts (P = 0.005), more severe hemorrhage (P < 0.0125), and lower HRQoL by parent, child, and proxy reporting (P < 0.05). Oral bleeding negatively impacted proxy-reported disease burden at diagnosis (P = 0.01). Persistence of disease and lower platelet counts at 6 and 12 month visits were the only factors noted to consistently impact quality of life beyond diagnosis for both parents and children.
CONCLUSIONS: HRQoL is low at diagnosis but significantly improves over time. Patients with ongoing disease and lower platelet counts continue to have significant disease burden.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  bleeding severity; childhood ITP; health-related quality of life

Mesh:

Year:  2017        PMID: 28111877     DOI: 10.1002/pbc.26405

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

Review 1.  Pediatric ITP: is it different from adult ITP?

Authors:  Jenny M Despotovic; Amanda B Grimes
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.

Authors:  Manuel Carcao; Mariana Silva; Michele David; Robert J Klaassen; MacGregor Steele; Victoria Price; Cindy Wakefield; Lussia Kim; Derek Stephens; Victor S Blanchette
Journal:  Blood Adv       Date:  2020-04-14

3.  Management strategies for newly diagnosed immune thrombocytopenia in Italian AIEOP Centres: do we overtreat? Data from a multicentre, prospective cohort study.

Authors:  Emilia Parodi; Giovanna Russo; Piero Farruggia; Lucia D Notarangelo; Maria T Giraudo; Margherita Nardi; Fiorina Giona; Paola Giordano; Ugo Ramenghi; Angelica Barone; Gianluca Boscarol; Simone Cesaro; Francesca Fioredda; Saverio Ladogana; Maria Licciardello; Francesca Rossi; Laura Rubert; Marco Spinelli; Fabio Tucci
Journal:  Blood Transfus       Date:  2020-07-22       Impact factor: 3.443

4.  Biological stratification of clinical disease courses in childhood immune thrombocytopenia.

Authors:  David E Schmidt; Katja M J Heitink-Pollé; Bart Mertens; Leendert Porcelijn; Rick Kapur; C Ellen van der Schoot; Gestur Vidarsson; Johanna G van der Bom; Marrie C A Bruin; Masja de Haas
Journal:  J Thromb Haemost       Date:  2021-03-18       Impact factor: 5.824

5.  A clinical prediction score for transient versus persistent childhood immune thrombocytopenia.

Authors:  David E Schmidt; Pernille Wendtland Edslev; Katja M J Heitink-Pollé; Bart Mertens; Marrie C A Bruin; Rick Kapur; Gestur Vidarsson; C Ellen van der Schoot; Leendert Porcelijn; Johanna G van der Bom; Steen Rosthøj; Masja de Haas
Journal:  J Thromb Haemost       Date:  2020-11-27       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.